COH04S1 and beta sequence-modified vaccine protect hamsters from SARS-CoV-2 variants.
Biological sciences
Immunology
Virology
Journal
iScience
ISSN: 2589-0042
Titre abrégé: iScience
Pays: United States
ID NLM: 101724038
Informations de publication
Date de publication:
17 Jun 2022
17 Jun 2022
Historique:
received:
16
02
2022
revised:
12
04
2022
accepted:
13
05
2022
pubmed:
1
6
2022
medline:
1
6
2022
entrez:
31
5
2022
Statut:
ppublish
Résumé
COVID-19 vaccine efficacy is threatened by emerging SARS-CoV-2 variants of concern (VOC) with the capacity to evade protective neutralizing antibody responses. We recently developed clinical vaccine candidate COH04S1, a synthetic modified vaccinia Ankara vector (sMVA) co-expressing spike and nucleocapsid antigens based on the Wuhan-Hu-1 reference strain that showed potent efficacy to protect against ancestral SARS-CoV-2 in Syrian hamsters and non-human primates and was safe and immunogenic in healthy volunteers. Here, we demonstrate that intramuscular immunization of Syrian hamsters with COH04S1 and an analogous Beta variant-adapted vaccine candidate (COH04S351) elicits potent cross-reactive antibody responses and protects against weight loss, lower respiratory tract infection, and lung pathology following challenge with major SARS-CoV-2 VOC, including Beta and the highly contagious Delta variant. These results demonstrate efficacy of COH04S1 and a variant-adapted vaccine analog to confer cross-protective immunity against SARS-CoV-2 and its emerging VOC, supporting clinical investigation of these sMVA-based COVID-19 vaccine candidates.
Identifiants
pubmed: 35634578
doi: 10.1016/j.isci.2022.104457
pii: S2589-0042(22)00728-3
pmc: PMC9126022
doi:
Types de publication
Journal Article
Langues
eng
Pagination
104457Subventions
Organisme : NCI NIH HHS
ID : P01 CA111412
Pays : United States
Organisme : NCI NIH HHS
ID : P50 CA107399
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA181045
Pays : United States
Organisme : NIAID NIH HHS
ID : U19 AI128913
Pays : United States
Informations de copyright
© 2022 The Author(s).
Déclaration de conflit d'intérêts
While unknown whether publication of this report will aid in receiving grants and contracts, it is possible that this publication will be of benefit to City of Hope (COH). COH had no role in the conceptualization, design, data collection, analysis, decision to publish, or preparation of the manuscript. D.J.D. and F.W. are co-inventors on patent application PCT/US2021/016247 which covers the design and construction of the synthetic MVA platform. D.J.D., F.W., and F.C. are co-inventors on PCT/US2021/032821 and 63/244,103 which cover the development of a COVID-19 vaccine. D.J.D. is a consultant for GeoVax Labs Inc. All remaining authors declare no competing interests. GeoVax Labs Inc. has taken a worldwide exclusive license for COH04S1 from COH.
Références
J Virol. 2013 Feb;87(3):1322-32
pubmed: 23152525
Proc Natl Acad Sci U S A. 1992 Nov 15;89(22):10847-51
pubmed: 1438287
N Engl J Med. 2022 Apr 21;386(16):1532-1546
pubmed: 35249272
Signal Transduct Target Ther. 2021 Mar 31;6(1):136
pubmed: 33790236
Nature. 2020 Jul;583(7818):834-838
pubmed: 32408338
Nature. 2021 Feb;590(7847):630-634
pubmed: 33276369
Science. 2021 May 21;372(6544):815-821
pubmed: 33853970
Blood. 2017 Jan 5;129(1):114-125
pubmed: 27760761
Nat Med. 2020 Nov;26(11):1694-1700
pubmed: 32884153
JAMA. 2021 Mar 2;325(9):821-822
pubmed: 33507218
Cell. 2021 May 27;184(11):2939-2954.e9
pubmed: 33852911
Nature. 2020 Mar;579(7798):270-273
pubmed: 32015507
Sci Adv. 2022 Aug 5;8(31):eabp9770
pubmed: 35921414
Lancet. 2021 Jan 9;397(10269):99-111
pubmed: 33306989
Nature. 2021 Feb;590(7845):320-325
pubmed: 33260195
PLoS Pathog. 2014 Nov 20;10(11):e1004524
pubmed: 25412505
N Engl J Med. 2021 Jun 10;384(23):2187-2201
pubmed: 33882225
N Engl J Med. 2021 Dec 2;385(23):2195-2197
pubmed: 34670038
NPJ Vaccines. 2021 Oct 28;6(1):129
pubmed: 34711815
Nature. 2021 Apr;592(7854):438-443
pubmed: 33690265
N Engl J Med. 2020 Feb 20;382(8):727-733
pubmed: 31978945
Cell. 2020 Jun 25;181(7):1489-1501.e15
pubmed: 32473127
Cell. 2022 Jan 6;185(1):113-130.e15
pubmed: 34921774
N Engl J Med. 2022 Feb 3;386(5):494-496
pubmed: 34965358
J Virol. 2018 Sep 12;92(19):
pubmed: 30045984
Nature. 2022 Feb;602(7898):682-688
pubmed: 35016197
Clin Infect Dis. 2020 Dec 3;71(9):2428-2446
pubmed: 32215622
Proc Natl Acad Sci U S A. 2020 Jul 14;117(28):16587-16595
pubmed: 32571934
N Engl J Med. 2021 Feb 4;384(5):403-416
pubmed: 33378609
Cell. 2021 Apr 29;184(9):2348-2361.e6
pubmed: 33730597
Nature. 2021 Aug;596(7871):276-280
pubmed: 34237773
Proc Natl Acad Sci U S A. 2021 Mar 23;118(12):
pubmed: 33688035
N Engl J Med. 2022 Apr 7;386(14):1377-1380
pubmed: 35297591
Cell Rep. 2020 Oct 6;33(1):108234
pubmed: 32979938
Nature. 2021 Aug;596(7872):423-427
pubmed: 34161961
Nat Med. 2021 Jul;27(7):1205-1211
pubmed: 34002089
Nature. 2020 Oct;586(7830):583-588
pubmed: 32731257
Ann Intern Med. 2020 Mar 3;172(5):306-316
pubmed: 32040960
NPJ Vaccines. 2022 Jan 21;7(1):7
pubmed: 35064109
Cell. 2021 Apr 29;184(9):2523
pubmed: 33930298
Adv Virus Res. 2017;97:187-243
pubmed: 28057259
Nat Commun. 2021 Jun 30;12(1):4048
pubmed: 34193869
Oncoimmunology. 2017 Aug 11;6(12):e1363138
pubmed: 29209571
N Engl J Med. 2021 May 20;384(20):1899-1909
pubmed: 33951374
N Engl J Med. 2021 Aug 12;385(7):585-594
pubmed: 34289274
Lancet Microbe. 2022 Apr;3(4):e252-e264
pubmed: 35287430
Nat Commun. 2020 Nov 30;11(1):6121
pubmed: 33257686
Viruses. 2021 Nov 16;13(11):
pubmed: 34835096
N Engl J Med. 2021 May 20;384(20):1885-1898
pubmed: 33725432
N Engl J Med. 2020 Dec 31;383(27):2603-2615
pubmed: 33301246
Vaccine. 2013 Sep 6;31(39):4241-6
pubmed: 23523410
Nat Med. 2021 Dec;27(12):2136-2143
pubmed: 34728831
Cell Rep. 2021 Sep 7;36(10):109664
pubmed: 34450033
Nat Commun. 2020 Dec 16;11(1):6402
pubmed: 33328475